Loading
A phase 1/2 trial of Furmonertinib and Carboplatin in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT07229599 by Minghui Pharmaceutical (Hangzhou) Ltd, with 300 participants planned, started 2025-05-09 and due to reach its primary completion in 2029-05. Interventions recorded: MHB036C for Injection, MHB039A for Injection, Furmonertinib and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MHB036C, MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB036C, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/